Chairpersons: Christopher Paul Cannon (Boston, United States of America), Dominick Joseph Angiolillo (Jacksonville, United States of America)

Subtitle: Sponsored by Boehringer Ingelheim

Learning Objectives: To review how the presentation of the RE-LY results 10 years ago heralded a decade of innovation in the non-Vitamin K antagonist oral anticoagulant (NOAC) treatment landscape – To assess the latest data and guideline recommendations for NOACs in various cardiology settings, including cardioversion, ablation and following percutaneous coronary intervention (PCI) – To provide practical guidence on the management of NOACs in these settings

From RE-LY to RE-DUAL PCI: a decade of innovation

Christopher Paul Cannon

Antithrombotic therapy post-PCI: is your practice keeping up with the guidelines?

Dominick Joseph Angiolillo

Antithrombotic therapy post-PCI: practical tips for challenging scenarios

Associate Professor Jurrien M ten Berg

Cardioversion, ablation, and devices: practical tips to treat your atrial fibrillation patients

Dhiraj Gupta

Panel discussion and questions and answers: NOACs in cardiac patients undergoing procedures